Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 18/20 | 0.80 |
| ▸ | BCL2 | P10415 | 14/20 | 0.80 |
| ▸ | BAD | Q92934 | 4/20 | 0.80 |
| ▸ | BCL2L2 | Q92843 | 2/20 | 0.80 |
| ▸ | BCL2L11 | O43521 | 1/20 | 0.80 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.80 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.80 |
| ▸ | ASPH | Q12797 | 1/20 | 0.80 |
| ▸ | VHL | P40337 | 3/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30200455 | 0.94 | BCL2L1 (0.84) | BCL2L1BCL2BADBCL2L2BCL2L11 | |
| SCHEMBL26647721 | 0.93 | BCL2L1 (0.82) | BCL2L1BCL2BADBCL2L2BCL2L11 | |
| SCHEMBL26647733 | 0.93 | BCL2L1 (0.82) | BCL2L1BCL2BADBCL2L2BCL2L11 | |
| SCHEMBL26648070 | 0.92 | BCL2L1 (0.80) | BCL2L1BCL2BADBCL2L2BCL2L11 | |
| SCHEMBL33530299 | 0.91 | BCL2L1 (0.77) | BCL2L1BCL2BADBCL2L2BCL2L11 | |
| SCHEMBL31450693 | 0.91 | BCL2L1 (0.77) | BCL2L1BCL2BADBCL2L2BCL2L11 | |
| SCHEMBL19475888 | 0.91 | BCL2L1 (0.91) | BCL2L1BCL2BADBCL2L2BCL2L11 | |
| SCHEMBL19475889 | 0.91 | BCL2L1 (0.91) | BCL2L1BCL2BADBCL2L2BCL2L11 | |
| SCHEMBL19503614 | 0.91 | BCL2L1 (0.81) | BCL2L1BCL2BADBCL2L2BCL2L11 | |
| SCHEMBL20956661 | 0.91 | BCL2L1 (0.81) | BCL2L1BCL2BADBCL2L2BCL2L11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4401729-A1 | BCL-XL DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2024-07-24 | — | — | EP | disclosed |
| WO-2023044046-A1 | BCL-XL DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-03-23 | — | — | WO | disclosed |